Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing

Cardiovascular Drugs and Therapy

Volumn 10, Issue 1, 1996, Pages 39-47

  Abou Mohamed, Gamal ^a   Nagarajan, Ravi ^a   Ibrahim, Tarek M ^b   Caldwell, Robert W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Adrenergic receptors; Animal; Arbutamine; Dobutamine; Guinea pigs; Hamster; In vitro; Isoproterenol; Rats; Sympathomimetic amines

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ADRENERGIC RECEPTOR; ARBUTAMINE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CATECHOLAMINE; ISOPRENALINE; METOPROLOL; NORADRENALIN; PROPRANOLOL; RECEPTOR SUBTYPE;

ADIPOCYTE; ADRENERGIC ACTIVITY; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; BROWN ADIPOSE TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROSTIMULATION; EXERCISE TEST; GUINEA PIG; HAMSTER; HEART LEFT ATRIUM; HEART MUSCLE CONTRACTILE FORCE; HEART RATE; HEART STRESS; ILEUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE RELAXATION; TRACHEA;

EID: 0029932170     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00051129     Document Type: Article

References (35)

1. McLaughlin PR, Martin RP, Doherty P, et al. Reproducibility of thallium-201 in myocardial imaging. Circulation 1977; 55:497-503.
2. Fung AY, Gallagher KP, Buda AJ. The physiologic basis of dobutamine as compared with dipyridamole stress interventions in the assessment of critical coronary stenosis. Circulation 1987;76:943-951.
3. Nagarajan R, Parthasrathy V, Makilzhan S, Balasubramanian V. Isoproterenol infusion - An alternative to exercise testing. Indian Heart J 1989;41:99-104.
4. Lockett M. Dangerous effects of isoprenaline in myocardial failure. Lancet 1965;2:104-106.
5. Johnson GL, Ehrrich SJ, El-Hage AN, Balazs T. Effects of antiarrhythmic agents on isoproterenol induced ventricular fibrillation in heavy rats: A possible model of sudden cardiac death. Res Commun Chem Pathol Pharmacol 1986;51: 351-364.
6. Tuttle RR, Mills J. Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36: 185-196.
7. Abou-Mohamed G, Caldwell RW, Ibrahim, TM, Tuttle RR. Integrative cardiovascular actions of a novel catecholamine, GP-2-128. J Cardiovasc Pharmacol 1994;23:485-491.
8. Tuttle RR, Hilman R, Wiesner J, et al. Closed-loop delivery and monitoring a catecholamine, arbutamine, for pharmacological stress testing: Preclinical evaluation (abstr). Pharmacologist 1991;33:177.
9. Nagarajan R, Abou-Mohamed G, Meyers T, Caldwell RW. A novel catecholamine, (arbutamine) for a pharmacological cardiac stress agent. Cardiovasc Drug Ther 1996;10: 31-38.
10. Young M, Pan W, Wiesner J, et al. Characterization of arbutamine: A novel catecholamine stress agent for diagnosis of coronary artery disease. Drug Dev Res 1994;32:19-28.
11. Van Rossum JM. Cumulative dose response curves: II - Technique for dose response curve in isolated organs and evaluation of drug parameters. Arch Int Pharmacodyn Ther 1965;143:299-330.
12. Abou-Mohamed G, Caldwell RW, Carrier GO, Elmazar MM, Tuttle RR. Interaction of a novel catecholamine, GP-128, with adrenergic receptors. J Cardiovasc Pharmacol 1994;23:492-500.
13. 2-adrenergic receptors. Eur J Pharmacol 1986;130:137-139.
14. Nedrergaard J, Lindberg O. The brown fat cell. Int Rev Cytol 1982;74:186-286.
15. Lambert M, Neisch AC. Rapid method for estimation of glycerol in fermentation solutions. Can J Res 1950;28: 83-89.
16. Arunlakashana O, Schild RD. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959;14: 48-58.
17. Furchgott RF, Bursztyn P. Comparison of dissociation constants and relative efficacies of selected agonists acting on parasympathetic receptors. NY Acad Sci 1967;139:882-899.
18. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
19. Winer BJ. Statistical Principles in Experimental Design, 2nd ed. New York: McGraw-Hill, 1971, pp 152-176, 11-196.
20. Previtali M, Lanzarini L, Ferrario M, Tortorici M, Mussini A, Montemartini C. Dobutamine versus dipyridamole echocardiography in coronary artery disease. Circulation, 1991; 83(Suppl III):27-31.
21. 2 adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 1979;16:34-36.
22. Brodde OE. β Adrenoceptors. In: Williams M, Glennon RA, Timmermans PB, eds. Receptor Pharmacology and Function. New York: Marcel Dekker, 1989, pp 207-255.
23. 2-adrenoceptors in the human heart: Properties function and alteration in chronic heart failure. J Pharmacol Rev 1991;43:203-342.
24. Benfey BG. Function of myocardial α-adrenoceptors. Life Sci 1990;46:743-757.
25. Arch JRS, Ainsworth AT, Cawthorne MA. Atypical β-receptor on brown adipocytes as target for anti-obesity drugs. Nature 1984;309:163-165.
26. Walter M, Lemoine H, Kaumann AJ. Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn-Schmiedebergs Arch Pharmacol 1984;327:159-175.
27. Wilson C, Wilson S, Piercy V, Sennitt MV, Arch RSJ. The rat lipolytic β-adrenergic receptors: Studies using novel β-adrenoceptor agonist. Eur J Pharmacol 1984;100:309-319.
28. Shen Y, Zhang H, Vatner SF. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther 1994;268:466-473.
29. Rand MJ, Tunge LH, Louis WJ, Story D. Cardiac α-adrenoceptors: Postjunctional and prejunctional. J Mol Cell Cardiol 1986;18(Suppl 5):17-32.
30. Schumann HJ, Wagner J, Knorr A, Reidemeister JC, Sadony V, Sachramm G. Demonstration in human atrial preparations of alpha adrenoceptors mediating positive inotropic effects. Naunyn-Schmiedebergs Arch Pharmacol 1978;302: 333-336.
31. Wagner J, Brodde OE. On the presence and distribution of alpha adrenoceptor in the heart of various mammalian species. Naunyn-Schmiedebergs Arch Pharmacol 1978;302: 239-254.
32. Ruffolo RR Jr, Morgan EL. Interaction of the novel inotropic agent, ASL-7022, with α- and β-adrenoceptors in the cardiovascular system of the pithed rat: Comparison with dobutamine and dopamine. J Pharmacol Exp Ther 1984; 229:364-371.
33. Bolter CP, Ledsome JR. Inotropic and chronotropic responses of the in vivo denervated dog myocardium to dobutamine. Can J Physiol Pharmacol 1976;54:618-621.
34. Vatner SF, McRitchie RJ, Braunwald E. Effects of dobutamine on the left ventricular performance, coronary dynamics and distribution of cardiac output in conscious dogs. J Clin Invest 1974;53:1265-1273.
35. Sakanashi M, Tomamatsu E, Takeo S, et al. Effect of dobutamine on coronary circulation and cardiac metabolism of the dog. Drug Res 1978;28:798-801.